Invicta Diagnostic Appoints M/s. Shrenik Nagaonkar & Associates as Secretarial Auditor for Five-Year Term

1 min read     Updated on 14 May 2026, 10:56 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Invicta Diagnostic Limited's Board of Directors appointed M/s. Shrenik Nagaonkar & Associates, Company Secretaries, as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30, at its meeting held on May 13, 2026. The appointment was made in compliance with the Companies Act, 2013 and SEBI (LODR) Regulations, 2015, and is subject to shareholder approval at the ensuing Annual General Meeting. Mr. Shrenik Nagaonkar, the firm's proprietor, holds over 19 years of experience in corporate governance, corporate laws, security laws, and capital markets, and is a fellow member of the Institute of Company Secretaries of India.

powered bylight_fuzz_icon
40282000

*this image is generated using AI for illustrative purposes only.

Invicta Diagnostic Limited announced the appointment of M/s. Shrenik Nagaonkar & Associates, Company Secretaries, as its Secretarial Auditor, following a resolution passed at the Board of Directors meeting held on May 13, 2026. The appointment covers a term of five financial years, from FY 2025-26 to FY 2029-30, and will be placed before shareholders at the ensuing Annual General Meeting for approval. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The Board meeting commenced at 7:30 p.m. (IST) and concluded at 8:20 p.m. (IST) on May 13, 2026. The appointment was communicated to the National Stock Exchange of India Limited by Sanket Vinod Jain, Chairman and Non-Executive Director of the company, from Mumbai.

Appointment Details

The key details of the appointment, as disclosed in Annexure I filed with the exchange, are summarised below:

Parameter: Details
Name: M/s. Shrenik Nagaonkar & Associates
Designation: Secretarial Auditor
Date of Appointment: Wednesday, 13 May, 2026
Term of Appointment: 5 (Five) years — FY 2025-26 to FY 2029-30
Reason for Appointment: Compliance with Companies Act, 2013 & SEBI (LODR) Regulations, 2015
Equity Shares Held in Company: NIL
Relationship with Directors: NIL

Profile of the Secretarial Auditor

Mr. Shrenik Nagaonkar is the proprietor of M/s. Shrenik Nagaonkar & Associates. He brings more than 19 years of experience in corporate governance, encompassing corporate laws, security laws, and capital markets. He is a fellow member of the Institute of Company Secretaries of India and holds a Master of Business Administration with specialisation in Finance. The firm is noted to be a peer-reviewed firm.

Regulatory Compliance

The appointment has been made to comply with the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As required under Regulation 30 of the Listing Regulations, the company has filed the relevant disclosures with the stock exchange. The appointment remains subject to shareholder ratification at the forthcoming Annual General Meeting.

Historical Stock Returns for Invicta Diagnostic

1 Day5 Days1 Month6 Months1 Year5 Years
+3.59%-0.56%+24.22%-7.45%-7.45%-7.45%

How might the appointment of a seasoned secretarial auditor with capital markets expertise influence Invicta Diagnostic's future compliance posture and potential regulatory actions?

Will shareholder approval of this appointment at the AGM signal broader confidence in Invicta Diagnostic's corporate governance reforms?

Could this strengthened compliance framework position Invicta Diagnostic for any upcoming fundraising activities, exchange upgrades, or regulatory filings?

Invicta Diagnostic Limited Completes 51% Stake Acquisition in Vinchurkar Diagnostics Private Limited

1 min read     Updated on 09 May 2026, 12:33 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Invicta Diagnostic Limited completed the acquisition of a 51% stake in Vinchurkar Diagnostics Private Limited on May 8, 2026, with shares credited to its demat account. The transaction was approved across Board Meetings held on January 5, March 25, and April 11, 2026, and disclosed under Regulation 30 of the SEBI (LODR) Regulations, 2015. All required regulatory details had been previously submitted to the National Stock Exchange of India Limited. The disclosure was authorised by Chairman and Non-Executive Director Sanket Vinod Jain from Mumbai.

powered bylight_fuzz_icon
39855798

*this image is generated using AI for illustrative purposes only.

Invicta Diagnostic Limited has formally completed the acquisition of a 51% stake in Vinchurkar Diagnostics Private Limited, with the transaction concluded on May 8, 2026. The company confirmed that the shares have been credited to its demat account, marking the formal completion of this acquisition.

Acquisition Details

The acquisition was disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The key details of the transaction are summarised below:

Parameter: Details
Target Company: Vinchurkar Diagnostics Private Limited
Stake Acquired: 51%
Completion Date: May 8, 2026
Regulatory Framework: Regulation 30, SEBI (LODR) Regulations, 2015
Share Credit Status: Credited to demat account

Board Approvals and Regulatory Background

The acquisition follows a series of Board Meetings held on the following dates, during which the transaction was deliberated and approved:

  • January 5, 2026
  • March 25, 2026
  • April 11, 2026

The company noted that all requisite details as required under Regulation 30, read with applicable SEBI Circulars, had already been submitted to the stock exchange through previous intimations and outcomes.

Disclosure and Authorisation

The disclosure was made by Sanket Vinod Jain, Chairman and Non-Executive Director of Invicta Diagnostic Limited (DIN: 08299039), from Mumbai, on May 8, 2026. The communication was addressed to the National Stock Exchange of India Limited and requested the exchange to take the update on record.

Historical Stock Returns for Invicta Diagnostic

1 Day5 Days1 Month6 Months1 Year5 Years
+3.59%-0.56%+24.22%-7.45%-7.45%-7.45%

How does Invicta Diagnostic plan to integrate Vinchurkar Diagnostics' operations, and what synergies are expected to materialize in the next 12-24 months?

Will Invicta Diagnostic pursue acquisition of the remaining 49% stake in Vinchurkar Diagnostics, and what is the timeline for potential full consolidation?

How will this acquisition impact Invicta Diagnostic's revenue and EBITDA margins in the upcoming quarterly results?

1 Year Returns:-7.45%